Clinical Experience with a New Anticoagulant, Dipaxin (2-diphenylacetyl-l,3-indandione)
- 1 February 1954
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 9 (2), 230-237
- https://doi.org/10.1161/01.cir.9.2.230
Abstract
Prothrombin levels as measured by the one-stage whole-plasma and the two-stage technics were followed in 80 patients receiving Dipaxin. The induction period is similar to that for Tromexan, namely, 48 to 60 hours and the recovery period 10 to 15 days which is somewhat longer than in the case of either Tromexan or Dicumarol. This recovery period is hastened to some degree by the administration of water-soluble vitamin K preparations and materially accelerated by vitamin K 1 . The prothrombin level during maintenance therapy is unusually stable. Transient bleeding occurred in two patients. No other toxic effects were observed.Keywords
This publication has 4 references indexed in Scilit:
- Effect in Man of a New Indandione Anticoagulant.Experimental Biology and Medicine, 1952
- Diphenylacetyl-l,3-Indandione as a Potent Hypoprothrombinemic AgentExperimental Biology and Medicine, 1952
- THE ONE-STAGE AND 2-STAGE PROTHROMBIN METHODS IN THE CONTROL OF DICUMAROL THERAPY, WITH REMARKS ON AC-GLOBULIN1949
- A QUANTITATIVE STUDY ON BLOOD CLOTTING: PROTHROMBIN FLUCTUATIONS UNDER EXPERIMENTAL CONDITIONSAmerican Journal of Physiology-Legacy Content, 1936